Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS as a Solution at Dose Levels 2.5 -5 mg and Tablets at Dose Levels 25 - 600 mg Administered to Healthy Male Subjects. A Randomised, Double-blind, Placebo-controlled Trial, Including an Intra-subject Bioavailability Comparison of 100 mg BI 1356 BS as Tablet and as Solution. BI 1356 BS as Tablet and as Solution

NCT02173665 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02173665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02173665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS as a Solution at Dose Levels 2.5 -5 mg and Tablets at Dose Levels 25 - 600 mg Administered to Healthy Male Subjects. A Randomised, Double-blind, Placebo-controlled Trial, Including an Intra-subject Bioavailability Comparison of 100 mg BI 1356 BS as Tablet and as Solution. BI 1356 BS as Tablet and as Solution
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2004
Completion date
Not reported
Enrollment
64 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy